ArticleOncology letters2025
Complete remission of recurrent uterine angiosarcoma following long-term systemic chemotherapy with paclitaxel and carboplatin: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiosarcoma (AS) is a rare and aggressive malignancy of vascular endothelial origin, accounting for 2-5% of all soft tissue sarcomas. Primary uterine AS is extremely rare, with only ~30 cases reported in English literature. Its prognosis remains poor, with a 5-year survival rate of <35%, and there is currently no standard systemic chemotherapy established for unresectable or recurrent cases. This study presents the case of a 57-year-old woman with a 27×20 cm uterine mass causing severe anemia (hemoglobin 4.5 g/dl). Following total hysterectomy and bilateral salpingo-oophorectomy, histopathological analysis confirmed primary uterine AS (T1NXM0). Despite complete surgical resection, three new intra-abdominal tumors appeared within 1 month. The patient underwent 21 cycles of intravenous paclitaxel and carboplatin every 3-4 weeks, achieving complete disappearance of all metastatic lesions. The patient was still alive 31 months after the initial surgery without any sign of recurrence or metastasis. This case demonstrates the potential efficacy of paclitaxel and carboplatin combination chemotherapy for recurrent uterine AS, contributing valuable data to guide future therapeutic strategies for this rare malignancy with typically poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.